Insider Purchases: Inside the Buy
Tag: featured-insiders
🛵 The Local Commerce Media Machine: Auditing DoorDash's $100M Insider Moat and the 33% Top-Line AI Acceleration
DoorDash may be building something much larger than a delivery app. With 33% revenue growth, improving profitability, a $100 million insider purchase, and potential AI commerce advantages, DASH remains one of the most fascinating platform stories in tech.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🧠 Cognizant (CTSH): The Impossible Float Monopoly, Project Leap, and a 9x Multiple GARP Arbitrage
Cognizant may be one of the market's most overlooked AI transformation stories. Strong bookings, aggressive buybacks, and a surprisingly cheap valuation suggest investors may be pricing the company too pessimistically.
🐋 StepStone Group (STEP): The $885B Private Market Juggernaut and the Great GAAP Optical Illusion
StepStone Group may be one of Wall Street's most misunderstood asset managers. Record fee-related earnings, $40 billion in dry powder, and a massive push into private wealth suggest the future may look brighter than headline GAAP losses imply.
🚀 Robinhood (HOOD): The $35M Insider Bet, the Great Wealth Transfer, and the Price of Fintech Dominance
Robinhood has evolved far beyond a commission-free trading app. With $307 billion in platform assets, 4.3 million Gold subscribers, and a $35 million insider purchase from fintech legend Meyer Malka, the company is increasingly positioning itself at the center of the next generation's financial lives.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.
🚀 Insperity (NSP): Why the CEO Just Bought Another $7.9M of This HR Stock
Insperity (NYSE: NSP) continues attracting major insider buying. CEO Paul Sarvadi has now purchased roughly $15.5 million of stock in less than three months, including a new $7.9 million purchase after shares rallied nearly 50%.
🚢 Norwegian Cruise Line (NCLH): Why Insiders Just Bought $27M of Stock
Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🪶 Goosehead Insurance (GSHD): The C-Suite Double-Down on a Deeply Plucked Stock
Goosehead Insurance has been deeply plucked, but insiders are buying the dip while Q1 adjusted EBITDA surged 57%. With a tech-enabled, asset-light broker model, institutional ownership above the float, and short interest near 8%, GSHD offers a risky but fascinating GARP setup.